Viatris (VTRS)
(Real Time Quote from BATS)
$8.80 USD
-0.18 (-2.00%)
Updated Aug 6, 2025 09:54 AM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VTRS 8.80 -0.18(-2.00%)
Will VTRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTRS
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Other News for VTRS
Viatris Inc. (VTRS) Announces New Board Appointment
Viatris Announces Appointment of David Simmons to the Company's Board of Directors | VTRS Stock News
Viatris Announces Quarterly Dividend | VTRS Stock News
Viatris declares $0.12 dividend
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week